BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy. METHODS: Endpoints were the rates and lengths of second remission, the cumulative incidence of second hematologic recurrence, second event-free survival (EFS), and survival. RESULTS: Bone marrow recurrences were isolated in 79 patients, and combined with an extramedullary site in 27 patients. The median time to recurrence was 2.6 years (range, 0.3-11.6 years). Seventy-six patients (71.7%) attained a second remission (median length, 0.7 year; range, 0.03-13.3 years). The 5-year survival probability among all patients was 24.2% +/- 4.2% (standard error). On multivariate analysis, time to first disease recurrence and blast cell lineage were found to be independent predictors of a second EFS (P = 0.008 and P = 0.028, respectively). The 5-year EFS estimate in patients with an initial disease remission of >/= 36 months was 42.6% +/- 7.8% but was only 12.5% +/- 3.9% among children with a short duration of disease remission (< 36 months). These estimates were 28.7% +/- 4.9% and 5.0% +/- 3.4%, respectively, for B blast and T blast cell lineages. CONCLUSIONS: Despite acceptable long-term second EFS rates for certain subgroups, overall bone marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome. (c) 2004 American Cancer Society.
BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy. METHODS: Endpoints were the rates and lengths of second remission, the cumulative incidence of second hematologic recurrence, second event-free survival (EFS), and survival. RESULTS: Bone marrow recurrences were isolated in 79 patients, and combined with an extramedullary site in 27 patients. The median time to recurrence was 2.6 years (range, 0.3-11.6 years). Seventy-six patients (71.7%) attained a second remission (median length, 0.7 year; range, 0.03-13.3 years). The 5-year survival probability among all patients was 24.2% +/- 4.2% (standard error). On multivariate analysis, time to first disease recurrence and blast cell lineage were found to be independent predictors of a second EFS (P = 0.008 and P = 0.028, respectively). The 5-year EFS estimate in patients with an initial disease remission of >/= 36 months was 42.6% +/- 7.8% but was only 12.5% +/- 3.9% among children with a short duration of disease remission (< 36 months). These estimates were 28.7% +/- 4.9% and 5.0% +/- 3.4%, respectively, for B blast and T blast cell lineages. CONCLUSIONS: Despite acceptable long-term second EFS rates for certain subgroups, overall bone marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome. (c) 2004 American Cancer Society.
Authors: Kimberly P Dunsmore; Meenakshi Devidas; Stephen B Linda; Michael J Borowitz; Naomi Winick; Stephen P Hunger; William L Carroll; Bruce M Camitta Journal: J Clin Oncol Date: 2012-06-25 Impact factor: 44.544
Authors: Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Nancy Eisenberg; Barbara L Asselin; Brent L Wood; Marcia S Leonard Rn; John Murphy; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger Journal: Pediatr Blood Cancer Date: 2015-03-08 Impact factor: 3.167
Authors: K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh Journal: Leukemia Date: 2008-09-25 Impact factor: 11.528
Authors: Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Jun J Yang; Deepa Bhojwani; Wenjian Yang; Xiangjun Cai; Gabriele Stocco; Kristine Crews; Jinhua Wang; Debra Morrison; Meenakshi Devidas; Stephen P Hunger; Cheryl L Willman; Elizabeth A Raetz; Ching-Hon Pui; William E Evans; Mary V Relling; William L Carroll Journal: Blood Date: 2008-09-02 Impact factor: 22.113
Authors: Richard H Ko; Lingyun Ji; Phillip Barnette; Bruce Bostrom; Raymond Hutchinson; Elizabeth Raetz; Nita L Seibel; Clare J Twist; Elena Eckroth; Richard Sposto; Paul S Gaynon; Mignon L Loh Journal: J Clin Oncol Date: 2009-10-19 Impact factor: 44.544
Authors: Mary Eapen; Elizabeth Raetz; Mei-Jie Zhang; Catherine Muehlenbein; Meenakshi Devidas; Thomas Abshire; Amy Billett; Alan Homans; Bruce Camitta; William L Carroll; Stella M Davies Journal: Blood Date: 2006-02-21 Impact factor: 22.113